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BACKGROUND: A low-grade state of adipose tissue inﬂammation associated with obesity has been linked to mechanisms
of systemic metabolic dysfunction. However, the relation of clinical phenotypes to depot-speciﬁc inﬂammation has not been
well examined in human obesity.
OBJECTIVE: To characterize the inﬂammatory status of subcutaneous and visceral fat depots, as assessed by tissue presence
of macrophage crown-like structures (CLS) as a hallmark of chronic inﬂammation, and determine the relation of systemic insulin
resistance to inﬂammatory abnormalities in subcutaneous and visceral fat.
METHODS: We collected adipose tissue simultaneously from subcutaneous and visceral (omental and mesenteric) depots in
92 obese participants (age 42±11years; BMIX30kgm
 2) during planned bariatric surgery. Using immunohistochemistry, we
categorized individuals as CLS
þ or CLS
  based on the presence or absence, respectively, of macrophage CLS in subcutaneous
(CLSs), omental (CLSo) and mesenteric (CLSm) adipose depots.
RESULTS: The majority of participants exhibited adipose tissue inﬂammation manifest by the presence of CLS (CLS
þ)i n
both subcutaneous and intra-abdominal visceral depots. CLS status in subcutaneous fat was highly sensitive and modestly
speciﬁc for inﬂammation of visceral fat. In multivariable models, plasma insulin and homeostatis model assessment levels
were positively associated with CLS
þ status in all depots independent of age, waist circumference, BMI and type 2 diabetes,
and worsened with the increasing number of adipose regions involved.
CONCLUSIONS: In severely obese participants, systemic insulin resistance is linked to adipose inﬂammation in both subcutaneous
and visceral depots. The ﬁndings suggest that examination of subcutaneous regions that are more easily accessible by
transcutaneous biopsy may prove useful in clinical studies designed to investigate adipose phenotypes in relation to
human disease.
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INTRODUCTION
Clinical studies consistently demonstrate a link between obesity
and increased risk for developing insulin resistance
1 and type 2
diabetes (T2DM).
2 The most recent national data show that the
majority of adults
3 and a third of children in the US are overweight
or obese.
4 Experts now predict that 165 million Americans (at least
50% of adults) will be obese by 2030 leading to a major public
health burden and cost.
5 While increased adiposity is associated
with metabolic and cardiovascular risks, a growing body of
evidence suggests that regional adiposity with selective accumu-
lation of intra-abdominal visceral fat may be more closely linked to
disease phenotypes than subcutaneous deposition.
6
A key mechanism in the pathogenesis of insulin resistance
linked to obesity relates to adipose tissue inﬂammation that has
been well demonstrated in experimental animal models and now
gaining recognition in clinical human disease.
7- -9 Inﬂammatory
changes in fat tissue appear to be driven by inﬁltration of adipose
tissue macrophages that support a chronic state of inﬂammation
strongly implicated in mechanisms of whole body metabolic
dysregulation.
10 We and others have shown that macrophage
accumulation in subcutaneous fat in a characteristic histopatho-
logical pattern consisting of crown-like structures (CLS) is
associated with altered adipose tissue gene expression, cytokine
overproduction, systemic insulin resistance and vascular endothe-
lial dysfunction in obese humans.
10- -12 These data support the
growing paradigm that both adipose tissue quality and quantity
may be relevant to disease mechanism in human obesity.
Although subcutaneous fat has been more extensively studied
owing to its easier access for clinical investigation, few studies
have simultaneously related ﬁndings to visceral depots.
12 Thus,
our primary objective was to determine whether the inﬂammatory
status of subcutaneous fat as assessed by the presence of
macrophage CLS relates to the state of inﬂammation in visceral
fat. Additionally, we sought to determine whether systemic insulin
resistance relates more closely to abnormalities in subcutaneous
versus visceral reserves in obese humans.
SUBJECTS AND METHODS
Participants
We consecutively enrolled obese (BMI X30kgm
 2) adult men and
women, ageX18 years scheduled for gastric bypass surgery at the Boston
Medical Center. The patient population was speciﬁcally composed of
subjects with severe long-standing obesity. Preoperative dietary regimens
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www.nature.com/nutdwere uniform for all subjects, consisting of a high ﬁber, low fat plan
with approximate daily calorie intake of 1200- -1500kcal for women
and 1500- -1800kcal for men.
13 Participants with unstable medical
conditions such as active coronary syndromes, congestive heart failure,
systemic infection, malignancy or pregnancy were excluded. Individuals
with a medical diagnosis of type 1 diabetes were also excluded.
Written informed consent was obtained from all participants. Study
approval was granted by the Boston University Medical Center Institutional
Review Board.
Adipose tissue collection and immunohistochemistry
In 92 obese individuals, approximately 1cm pieces of adipose tissue were
collected intra-operatively from three separate depots (subcutaneous,
omental and mesenteric) by the surgeon during the initial stages of
planned gastric bypass surgery. Biopsies were secured from regions
deemed medically safe by the operating surgeon based on personal
experience and were uniformly the same for each patient. Visceral fat was
secured from the free edges of the greater omentum and the mesenteric
appendices epiploicae of the transverse colon. The subcutaneous fat
removed intraoperatively represented the same anatomic layer that would
be accessed by a transcutaneous biopsy procedure lateral to the umbilicus.
All the tissue samples were immediately stored in formalin or promptly
frozen in liquid nitrogen to be stored at  801C. Each participant provided
a single biopsy specimen from each depot for analysis. Immunohisto-
chemical stains were performed in the Department of Anatomic Pathology
at the Boston Medical Center as previously described.
11 Inﬁltration of
macrophage cell populations into adipose tissue was characterized
using cell-speciﬁc stains targeted to CD68 (predilute antibodies from
DakoCytomation Corporation, Glostrup, Denmark). All samples were
evaluated by a single pathologist (LJ) blinded to all clinical data.
CLS status was assessed after examination of all ﬁelds available per
slide at high-power ﬁeld (HPF) magniﬁcation using light microscopy.
A CLS was deﬁned as CD68
þ macrophage aggregates comprising at least
50% of the circumference circularly surrounding necrotic adipocytes.
Subcutaneous, omental and mesenteric fat depots from each participant
were dichotomously categorized based on the presence (CLS
þ)o r
absence (CLS
 ) of CLS in fat. In additional analyses, CLS
þ depots were
characterized as low density (1 CLS per HPF) or high density (X2 CLS per
HPF). An illustration of two adjacent macrophage CLS (high-density CLS) is
displayed in Figure 1. Participants were further categorized by depot-
speciﬁc CLS status in subcutaneous (CLSs) and omental fat depots (CLSo)
as follows: (1) CLS
  in all depots, (2) CLSs
þ and CLSo
  and (3) CLSs
þ and
CLSo
þ. The data were similarly analyzed based on CLSs and CLSm
(mesenteric) status.
Anthropometric and metabolic measures
During a single outpatient visit before planned bariatric surgery, weight,
height and BMI were recorded for each participant by trained personnel.
Weight was obtained using a calibrated scale (Ohaus, Pine Brook, NJ, USA).
Waist circumference was measured at the midpoint between the lowest rib
and top of the iliac crest. All biochemical analyses were performed by the
Boston Medical Center clinical chemistry laboratory, quantiﬁed from blood
samples collected in a fasted state. Measured variables included plasma
glucose, insulin, glycated hemoglobin A1c, total cholesterol, LDL-choles-
terol, HDL-cholesterol, triglycerides and high-sensitivity C-reactive protein.
Homeostatis model assessment (HOMA) was used as the index of insulin
sensitivity.
14
Statistical analyses
Histograms and normal Q-Q plots were inspected to determine if
continuous variables were normally distributed. Several clinical variables
were not normally distributed (cholesterol, glucose, HbA1c, BMI, high-
sensitivity CRP, insulin and HOMA) and were natural logarithm transformed
accordingly. Data are presented as mean±s.d. for normally distributed
data or median with inter-quartile range for skewed data. We calculated
sensitivity, speciﬁcity, positive predictive (PPV) and negative predictive
value (NPV) of CLSs±status for determining visceral CLSo and CLSm±
categorization. We examined whether CLSs, CLSo and CLSm status were
associated with markers of insulin resistance and glycemic parameters
(that is, natural log transformed HOMA, insulin, glucose and HbA1c) in
separate multivariable models using analysis of covariance (ANCOVA).
Waist circumference and BMI were strongly correlated (r¼0.85, Po0.0001
by Pearson’s correlation). To avoid colinearity, waist circumference
was regressed onto BMI and the residuals used (WCR). Models were
adjusted for age, WCR, BMI and T2DM status. Owing to the small number
of male participants (14%), we chose to not adjust for sex. However,
analyses were repeated in women only and results remained similar to
total cohort analyses. Next, we determined whether insulin resistance
was associated with both subcutaneous and omental CLS status by
ANCOVA with models adjusted as described above. Paired comparisons
between CLSs, CLSo and CLSm groups were conducted by Tukey’s post hoc
tests. Analyses were repeated using both subcutaneous and mesenteric
CLS status.
RESULTS
The clinical characteristics of all 92 participants (age 42±11 years)
that participated in the study are displayed in Table 1. The
majority of individuals were women (86%) with longstanding class
III obesity (BMI X40kgm
 2, 78%). Most participants exhibited
evidence of impaired insulin sensitivity (HOMA42.0, 72%) and
over a third had T2DM. For the group as a whole, the prevalence
of CLS
þ was highest in the subcutaneous depot and lowest in the
omental region. Few men were CLSs
  (n¼0), CLSo
  (n¼2) or CLSm
 
(n¼1). The sensitivity of CLSs for CLSo and CLSm status was high
(94% and 95%, respectively) with modest speciﬁcity (43% and
57%, respectively). The PPV and NPV of CLSs for CLSo status were
68% and 85%, respectively, and for CLSm values were 85% for both
PPV and NPV.
We explored whether CLSs
þ, CLSo
þ and CLSm
þ was associated
with markers of insulin resistance and glycemic parameters
(HOMA, insulin, glucose and HbA1c) in multivariable models
adjusted for age, WCR, BMI and T2DM. As shown in Figure 2a--d,
CLSs
þ was associated with increased HOMA (P¼0.01) and insulin
(P¼0.02) but not glucose (P¼0.71) or HbA1c (P¼0.69). The same
relationships were evident in the mesenteric depot, where CLSm
þ
was associated with increased HOMA (P¼0.05) and insulin
(P¼0.04) but not glucose (P¼0.60) or HbA1c (P¼0.83). Similarly,
CLSo
þ was associated with higher HOMA (P¼0.02), insulin
(P¼0.02) and positively trended for HbA1c (P¼0.08); while
glucose was not different between groups (P¼0.80). When
participants without T2DM were analyzed separately (n¼56),
Figure 1. Representative histological illustration of inﬂamed adipose
tissue as demonstrated by light microscopy. CD68
þ macrophages
(brown color) are organized into two separate ‘crown-like structures’
(indicated by arrows) surrounding individual adipocytes. (a)  20
Power; (b)  40 Power.
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signiﬁcance (Po0.05) only for the subcutaneous depot (data not
shown). There were no hypoglycemic medication-speciﬁc effects
on CLS status for each depot. Waist circumference remained a
signiﬁcant predictor of HOMA and insulin in all models. Analyses
repeated after excluding male participants (n¼13) did not alter
the results. We performed additional analyses based on CLS
density in adipose tissue. As shown in Table 2 , a minority o20%
of adipose depots exhibited high-density CLS (X2/HPF) as
illustrated in Figure 1. There were no signiﬁcant differences in
glucose, insulin or HOMA in subjects with low as compared to
high CLS density in any adipose depot.
Additionally, we investigated the relation of HOMA to
adipose inﬂammation in analyses combining subcutaneous
and omental fat tissue CLS status, adjusted for age, WCR,
BMI and T2DM. Among all participants, 17, 23 and 49 subjects
Table 1. Clinical characteristics
n¼92
Age, years 42±11
Female/male, n (%) 79 (86)/13 (14)
BMI, kgm
 2 44 (10)
BMIX40kgm
 2, n (%) 72 (78.3)
Waist circumference, cm 113±7.2
Glucose, mgdl
 1 97.0 (25.5)
Insulin, uIUml
 1 12.0 (11.0)
HOMA-IR 3.1 (3.0)
HgA1c, % 5.8 (1.3)
Total cholesterol, mgdl
 1 179 (45)
LDL cholesterol, mgdl
 1 115±33
HDL cholesterol, mgdl
 1 47±12
Triglycerides, mgdl
 1 118±61
Hs-CRP, mgdl
 1 4.9 (6.8)
Type 2 diabetic, n (%) 36 (39)
Metformin use, n (%) 32 (35)
Sulfonylurea use, n (%) 10 (11)
Thiazolidinedione use, n (%) 8 (9)
Insulin use, n (%) 6 (7)
Adipose crown-like structure+,
n (%)
Total Female Male
Subcutaneous 72 (78.3) 59 (74.7) 13 (100)
Omentum 52 (56.6) 41 (51.9) 11 (84.6)
Mesentery 62 (67.4) 50 (63.3) 12 (92.3)
Abbreviations: BMI, body mass index; HgA1c, glycated hemoglobin A1c;
HOMA-IR, homeostatis model assessment-insulin resistance; Hs-CRP, high-
sensitivity C-reactive protein. Data are presented as mean±s.d. or median
(inter-quartile range) or proportion, n (%).
Figure 2. (a-d) Relation of subcutaneous, omental and mesenteric adipose tissue crown-like structures (CLS) status to plasma (a) HOMA
(b) insulin (c) glucose and (d) HbA1c. Data are adjusted for age, WCR, BMI and prevalent T2DM. Data are presented as means±s.e., *Po0.05 or
wP¼0.05 for CLS
þ vs CLS
  within each speciﬁc depot. ln¼natural logarithm.
Table 2. CLS density by adipose tissue depot
Depot CLS categorization
None (0) 1/HPF
(low density)
X2/HPF
(high density)
Subcutaneous 20 (21.7) 56 (60.8) 16 (17.4)
Omental 40 (43.5) 49 (53.3) 3 (3.3)
Mesentery 30 (32.6) 55 (59.8) 7 (7.6)
Abbreviations: CLS, crown-like structure; HPF, high-power ﬁeld. Data are
presented as n (%).
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 /CLSo
 , CLSs
þ/CLSo
  and CLSs
þ/CLSo
þ, respectively.
Only three participants were CLSs
 /CLSo
þ and were excluded
from these sets of analyses, which did not affect the results.
As shown in Figure 3a, HOMA and insulin increased in a
graded pattern, with the CLSs
 /CLSo
  group demonstrating the
lowest and CLSs
þ/CLSo
þ group exhibiting the highest HOMA
and insulin values (Po0.05). Analyses were repeated using data
from mesenteric depots, and 17, 13 and 59 participants were
CLSs
 /CLSm
 , CLSs
þ/CLSm
  and CLSs
þ/CLSm
þ, respectively. Owing to
small numbers (n¼3), CLSs
 /CLSm
þ were excluded from analysis.
Similar to the omental depot analyses, HOMA and insulin increased
across groups with increasing degrees of depot-speciﬁc inﬂamma-
tion as shown in Figure 3b. Again, waist circumference remained a
signiﬁcant predictor of HOMA and insulin in all models. Excluding
men (n¼13) from the analyses did not alter the results.
DISCUSSION
In this study of severely obese individuals undergoing gastric
bypass surgery, we demonstrated that the majority of participants
exhibited evidence of adipose tissue inﬂammation as manifest by
the presence of macrophage CLS (CLS
þ) in both subcutaneous
and intra-abdominal visceral (omental and mesenteric) depots.
CLS
þ status in subcutaneous fat was strongly associated with
CLS
þ in each visceral depot with high sensitivity (X94%) and
modest speciﬁcity. Increased HOMA and insulin levels were
independently linked to inﬂammatory activation in all depots
and worsened in a graded fashion with increasing number of
adipose regions involved. These ﬁndings suggest that whole body
metabolic dysfunction is linked to qualitative changes in several
human adipose stores simultaneously. In this regard, examination
of subcutaneous fat that is more easily accessible by transcuta-
neous biopsy may provide a window into pathophysiological
alterations within deeper visceral depots.
To our knowledge this is the ﬁrst human study that system-
atically examined the association between CLS status in sub-
cutaneous adipose tissue (SAT) and two separate visceral adipose
tissue (VAT) regions collected from both the omentum and
mesentery. Our results in association with other studies using
paired subcutaneous and visceral fat samples in humans
15,16 and
mice
15,17,18 show that obesity-related macrophage accumulation
occurs in multiple adipose regions. While VAT has been shown to
differ in inﬂammatory transcriptome and secretory capacity,
ascribing it a proﬁle potentially more pathogenic compared to
SAT, studies have largely been in experimental animal models and
in vitro conditions.
19- -22 Recent clinical data in fact show that the
progression from the lean to obese state is associated with largely
parallel alterations in metabolic and immunoregulatory gene
expression proﬁles in both VAT and SAT that correlate with both
fat mass and measures of insulin sensitivity.
23 While visceral fat
mass is regarded as an important determinant of cardiometabolic
risk, evidence from the Framingham Heart Study suggests that
both subcutaneous and visceral loads relate to atherogenic
biomarkers.
24,25 Our ﬁndings are in line with several other clinical
studies showing a clear association between inﬂammation in SAT
and systemic insulin resistance.
10- -12,26,27 Additionally, we provide
novel data by demonstrating concordant inﬂammatory abnorm-
alities as deﬁned by CLS status in VAT and SAT in human obesity.
Considering the high degree of difﬁculty in securing visceral fat
samples from human participants, our ﬁndings suggest that
inﬂammation in SAT may serve as a reasonable proxy of
inﬂammatory status in VAT, lending support to the notion that
signiﬁcant clinical information may well be learned by qualitative
analysis of SAT in relation to systemic disease.
11,12,26- -30
Numerous experimental studies in mice show that adipose
tissue inﬂammation driven by inﬁltration of proinﬂammatory
macrophage populations is mechanistically linked to the devel-
opment of insulin resistance.
31,32 A direct role of adipose immune
activation in impaired insulin metabolism in humans is also
growing recognition. Adipose macrophage density
11,33 and
adipose mRNA CD68 expression
34 correlate with insulin resistance
and impaired glucose tolerance that decrease with weight loss.
35
Adipose tissue macrophages express cytokines such as TNF-a and
interleukins that have direct roles in mediating insulin resis-
tance.
9,12,36 In particular, accumulation of macrophages in patterns
of CLS aggregating around necrotic adipocytes
15 as a sign of
chronic tissue inﬂammation is associated with diseased clinical
phenotypes, including metabolic dysfunction and proathero-
sclerotic vascular abnormalities manifest as impaired endothelial
function.
11,37 Our prior work has demonstrated that inﬂammatory
activation of adipose stores is much more heterogeneous than in
animal models, as obese individuals with reduced inﬂammation
display favorable cardiometabolic proﬁles that are polarized
toward a lean phenotype, despite their signiﬁcant excess fat
burden.
11,37,38 Although the temporal relationship of depot-
speciﬁc inﬂammation in the initial stages of weight gain are
unknown, we demonstrate that both SAT and VAT exhibit
histopathological abnormalities that are linked to insulin resis-
tance in advanced human obesity.
Novel to this study, we demonstrated that individuals with
subcutaneous-visceral ‘double positives’ (CLSs
þ and CLSo
þ/CLSm
þ),
Figure 3. (a, b) Relation of plasma measures of insulin resistance
and glycemic parameters to adipose inﬂammation by combined
analyses of (a) subcutaneous-omental and (b) subcutaneous-
mesenteric CLS status. Data are adjusted for age, WCR, BMI and
prevalent T2DM. Data are presented as mean±s.e., *Po0.05 or
wP¼0.05 for comparisons with the CLSs
 /CLSo
  or CLSs
 /CLSm
  groups.
ln¼natural logarithm.
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plasma insulin compared with the ‘double negatives’ (CLSs
  and
CLSo
 /CLSm
 ). Mixed phenotypes of CLSs
þ and CLSo
 /CLSm
  displayed
intermediate values, suggesting that both depots likely incremen-
tally contribute to mechanisms of insulin resistance. We found no
difference in plasma HbA1c and glucose between the various CLS
groups, likely due to treatment-bias effects of hypoglycemic
agents in diabetic participants. Our overall ﬁndings were
directionally similar but relatively underpowered when individuals
with diabetes were excluded from the analyses. We demonstrated
that waist circumference remained a signiﬁcant independent
predictor of HOMA and insulin after adjustment for potential
confounders including age, BMI and CLS status, supporting the
notion that several different factors relating to adipose tissue
quality, quantity and regional distribution are all relevant to
shaping clinical disease phenotypes.
37,39,40
Our present study has several limitations. We relied on a single
biopsy site from each depot to minimize the surgical bleeding risk
from multiple biopsies, thus it remains plausible that multi-site
sampling could have reduced the number of false negatives from
a speciﬁc region. Moreover, we did not observe a statistically
signiﬁcant relation between CLS density and insulin resistance
likely owing to the low number (o20%) of individuals that
exhibited abundant tissue CLS based on our classiﬁcation scheme.
However, these limitations are counterbalanced by the relatively
large sample size allowing for multivariate analyses in this invasive
human study that examined paired samples from two distinct
visceral depots, unlike any prior clinical study. We used HOMA as
our index variable but acknowledge that it represents an
approximation of systemic insulin resistance.
14 Euglycemic clamp
studies may provide more robust relationships but in our opinion
are difﬁcult to perform in such severely obese individuals. We
were not able to quantify degree of visceral fat burden using
imaging such as CT/MRI as most of our severely obese cohort does
not ﬁt into standard imaging machines owing to size constraints.
We acknowledge that in lower weight categories, insulin-resistant
individuals may exhibit higher visceral fat loads compared with
the insulin-sensitive populations. We phenotyped adipose tissue
based on macrophage CLS status but understand that this
represents only a limited aspect of complex immunoregulatory
and functional alterations that develop in adipose reserves in
association with weight excess. Lastly, owing to the small number
of male participants, we were unable to perform sex-speciﬁc
analyses. However, our female predominance reﬂects the general
bariatric practice nationally and sex differences in populations that
seek weight loss intervention.
41
CONCLUSION
In severely obese participants undergoing bariatric surgery,
systemic insulin resistance was linked to adipose tissue inﬂamma-
tion in both subcutaneous and visceral depots. Sensitivity of
adipose inﬂammation assessed by the presence of macrophage
CLS in SAT for VAT was high (X94%). The ﬁndings suggest that
subcutaneous inﬂammatory status may serve as a reasonable
indicator of inﬂammation in visceral depots and that both depots
appear to contribute to systemic insulin resistance. We speculate
that much can be learned from studying subcutaneous fat that is
easily accessible by transcutaneous biopsy, thus permitting serial
examination of treatment interventions designed to modulate
adipose tissue phenotypes in human clinical studies.
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